Holen Sie sich die Stockscreener-App
54.48
2.44%
-1.37
Schlusskurs vom Vortag:
$55.85
Offen:
$54.76
24-Stunden-Volumen:
403.52K
Relative Volume:
0.39
Marktkapitalisierung:
$4.50B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-64.16M
KGV:
-42.89
EPS:
-1.2702
Netto-Cashflow:
$-69.06M
1W Leistung:
-0.44%
1M Leistung:
+36.05%
6M Leistung:
+107.03%
1J Leistung:
+77.20%
1-Tages-Spanne:
$53.94
$55.44
1-Wochen-Bereich:
$52.51
$57.88
52-Wochen-Spanne:
$14.80
$57.88
Cg Oncology Inc Stock (CGON) Company Profile
Firmenname
Cg Oncology Inc
Sektor
Branche
Telefon
(949) 419-6203
Adresse
400 SPECTRUM CENTER DRIVE, IRVINE
Vergleichen Sie CGON mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CGON
Cg Oncology Inc
|
54.44 | 4.61B | 0 | -64.16M | -69.06M | -1.2702 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.89 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
748.65 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
813.59 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.52 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Cg Oncology Inc Stock (CGON) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-11 | Eingeleitet | Wedbush | Outperform |
| 2025-11-24 | Eingeleitet | Truist | Buy |
| 2025-10-08 | Eingeleitet | Guggenheim | Buy |
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2025-07-10 | Fortgesetzt | Goldman | Buy |
| 2025-05-02 | Eingeleitet | JP Morgan | Overweight |
| 2025-04-16 | Eingeleitet | Scotiabank | Sector Perform |
| 2025-01-07 | Eingeleitet | TD Cowen | Buy |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-09-23 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-08-28 | Eingeleitet | ROTH MKM | Buy |
| 2024-06-28 | Eingeleitet | BofA Securities | Buy |
| 2024-02-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-02-20 | Eingeleitet | Goldman | Neutral |
| 2024-02-20 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-02-14 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Cg Oncology Inc Aktie (CGON) Neueste Nachrichten
Bladder Cancer Vaccines Market Poised for Rapid Growth at 21.32% - openPR.com
CG Oncology stock hits all-time high at 57.4 USD By Investing.com - Investing.com Nigeria
CG Oncology (NASDAQ:CGON) Sets New 52-Week HighShould You Buy? - MarketBeat
What Analysts Are Saying About CG Oncology Stock - Benzinga
CGON: RBC Capital Raises Price Target to $73, Maintains Outperfo - GuruFocus
CG Oncology stock hits all-time high at 57.4 USD - Investing.com
Portfolio Shifts: Can CG Oncology Inc expand into new marketsQuarterly Trade Review & Consistent Income Trade Recommendations - baoquankhu1.vn
Profit Review: What are CG Oncology Incs earnings expectationsChart Signals & Fast Moving Trade Plans - baoquankhu1.vn
Assessing CG Oncology (CGON) Valuation After Accelerated PIVOT-006 Phase 3 Trial Timeline - Sahm
Investment Review: Can CG Oncology Inc sustain earnings growthEarnings Performance Report & High Win Rate Trade Tips - baoquankhu1.vn
Midday Stock Roundup: loanDepot Jumps on Trump’s Proposed Mortgage Plan - Orange County Business Journal
Revenue Check: Is CG Oncology Inc stock a hidden gemRate Hike & Risk Managed Investment Signals - baoquankhu1.vn
Gainers Report: Is Citigroup Capital XVI Preferred Security stock undervalued right nowEarnings Summary Report & Safe Entry Momentum Stock Tips - baoquankhu1.vn
CGON: Pivotal data and regulatory milestones position a novel NMIBC therapy for major market expansion - TradingView — Track All Markets
CG Oncology Stock Rallies Nearly 32% in a Week: Here is Why - Finviz
CG Oncology Expands At-The-Market Equity Offering Capacity - The Globe and Mail
CG Oncology Accelerates Phase 3 Data Readout to First Half of 2026 - Intellectia AI
Why CG Oncology Stock Is Suddenly Climbing Higher - TipRanks
Oncolytics Biotech Inc. Appoints John McAdory as Executive Vice President of Strategy and Operations - marketscreener.com
Travel Stocks: What is the target price for CG Oncology Inc stock2025 Short Interest & Reliable Trade Execution Plans - baoquankhu1.vn
Mulay, James sells CG Oncology (CGON) shares for $584,798 By Investing.com - Investing.com Australia
Aug Highlights: Will CG Oncology Inc outperform the market in YEARPortfolio Risk Summary & Detailed Earnings Play Alerts - baoquankhu1.vn
Mulay, James sells CG Oncology (CGON) shares for $584,798 - Investing.com
CG Oncology files amendment to increase stock offering to $550 million By Investing.com - Investing.com Nigeria
James Mulay Sells 11,145 Shares of CG Oncology (NASDAQ:CGON) Stock - MarketBeat
CG Oncology files amendment to increase stock offering to $550 million - Investing.com
CG Oncology Files Amendment to Increase Stock Offering - TradingView — Track All Markets
Aug Spikes: Is Skeena Resources Limited attractive for institutional investorsDollar Strength & Weekly Top Stock Performers List - baoquankhu1.vn
CG Oncology, Inc. (CGON) Reports Q3 Loss, Tops Revenue Estimates - MSN
Institution Moves: Why analysts upgrade CG Oncology Inc. stockJuly 2025 Fed Impact & AI Enhanced Trading Signals - Bộ Nội Vụ
Truist Securities raises CG Oncology stock price target to $66 on early trial data - Investing.com Canada
Midday Stock Roundup: Staar Down 4% on Board Changes - Orange County Business Journal
Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026 - Benzinga
Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026 - Sahm
CG Oncology Expedites PIVOT-006 Phase 3 Topline Data Readout In Intermediate-Risk NMIBC To H1 2026 - Nasdaq
CG Oncology stock (CGON) jumps 29% on faster Phase 3 timeline — what to watch next week - TechStock²
CG Oncology stock (CGON) jumps 29% on faster PIVOT-006 Phase 3 readout — what to watch next - TechStock²
CG Oncology: 'Strong Buy' On Earlier Than Expected Completed Recruitment Cretostimogene - Seeking Alpha
CG Oncology stock jumps 29% on faster Phase 3 PIVOT-006 data clock — what to watch next - TechStock²
Assessing CG Oncology (CGON) Valuation After Strong Recent Share Price Momentum - Sahm
CG Oncology accelerates timeline for bladder cancer trial data By Investing.com - Investing.com Nigeria
Cg Oncology stock hits 52-week high at 46.19 USD By Investing.com - Investing.com Nigeria
Is CG Oncology Inc. stock supported by strong cash flowsJuly 2025 Setups & High Accuracy Swing Trade Signals - ulpravda.ru
CG Oncology (CGON) Is Up 29.7% After Accelerating PIVOT-006 Phase 3 TimelineHas The Bull Case Changed? - Yahoo Finance
Is CG Oncology (CGON) Stock Pricing In Its Recent 79% One Year Surge? - Yahoo Finance
CG Oncology’s Bladder Cancer Bet Heads Toward A Big 2026 Test - Finimize
Accelerated PIVOT-006 Timeline and Expanded NMIBC Opportunity Drive CG Oncology Target Hike to $108 and Reinforce Buy Rating - TipRanks
CG Oncology Gains Momentum as Price Targets and Investor Confidence Rise - StocksToTrade
CG Oncology Price Target Raised Amid Robust Market Prospects - timothysykes.com
CG Oncology stock price target raised to $93 from $89 at Morgan Stanley - Investing.com Canada
Accelerated Creto Trajectory in NMIBC Drives Earlier Data, De-Risked Commercialization, and Higher $66 Target Supporting Buy Rating on CG Oncology - TipRanks
Finanzdaten der Cg Oncology Inc-Aktie (CGON)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.38%
1.95%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):